stella
Prostate CancerJuly 2022Summary reviewed June 2026

Guided Ultrasound Heat Cleared Prostate Cancer in 88% of Men After Two Years

Researchers tested a targeted ultrasound treatment that uses MRI to guide heat energy to destroy cancer in one area of the prostate. In men with intermediate-risk prostate cancer, 88% had no cancer in the treated area after two years.

What the trial was testing

The trial enrolled 101 patients with prostate cancer. The study was sponsored by InSightec and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was mid-stage testing (phase 2/3). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

88% of men had no cancer in the treated area two years after a single ultrasound treatment.

The Lancet. Oncology · 2022 · NCT01657942

These findings — that nearly 9 in 10 men showed no cancer in the treated prostate area two years later — were published in the The Lancet. Oncology and represent the headline result of the study.

Researchers tracked outcomes across 101 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with prostate cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This was a mid-stage study testing whether focused ultrasound could treat prostate cancer without removing the entire prostate. The results are promising, but this specific approach is not yet widely available as a standard treatment. If you have intermediate-risk prostate cancer, ask your doctor whether you might qualify for a clinical trial testing focal treatments or what standard options are best for you.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.